Abstract
The aim of the study was to develop a new diagnostic biomarker for identifying serum exosomal miRNAs specific to epithelial ovarian cancer (EOC) and to find out target gene of the miRNA for exploring the molecular mechanisms in EOC. A total of 84 cases of ovarian masses and sera were enrolled, comprising EOC (n = 71), benign ovarian neoplasms (n = 13). We detected expression of candidate miRNAs in the serum and tissue of both benign ovarian neoplasm group and EOC group using real-time polymerase chain reaction. Immunohistochemistry were constructed using formalin fixed paraffin embedded (FFPE) tissue to detect expression level of suppressor of cytokine signaling 4 (SOCS4). In the EOC group, miRNA-1290 was significantly overexpressed in serum exosomes and tissues as compared to benign ovarian neoplasm group (fold change ≥ 2, p < 0.05). We observed area under the receiver operating characteristic curve (AUC) for miR-1290, using a cut-off of 0.73, the exosomal miR-1290 from serum had AUC, sensitivity, and specificity values of 0.794, 69.2 and 87.3, respectively. In immunohistochemical study, expression of SOCS4 in EOC was lower than that in benign ovarian neoplasm. Serum exosomal miR-1290 could be considered as a biomarker for differential diagnosis of EOC from benign ovarian neoplasm and SOCS4 might be potential target gene of miR-1290 in EOC.
Highlights
Ovarian cancer is the second most common cancer among in women worldwide, accounting for about 2.5% of all cancers in women, but has the highest mortality rate of about 5 percent of all cancers; the 5-year survival rate of ovarian cancer is 90% in stage I and 75% in stage II, but less than 30% in stages III and IV [1]
Tumor marker cancer 125 (CA125) was above normal range around 80% in epithelial ovarian cancer (EOC) group and over 25% in benign ovarian neoplasm group (p < 0.001)
Benign neoplasm, and wethe confirmed the expression of tissue miR1246 and miR-1290 were ovarian neoplasm, we confirmed thatthan the expression of tissue miR1246 andneoplasm, miR-1290 statistically higherand in patients with EOC
Summary
Ovarian cancer is the second most common cancer among in women worldwide, accounting for about 2.5% of all cancers in women, but has the highest mortality rate of about 5 percent of all cancers; the 5-year survival rate of ovarian cancer is 90% in stage I and 75% in stage II, but less than 30% in stages III and IV [1]. Since it was first described in 1983 by Bast et al that CA125 was expressed increasingly in epithelial ovarian cancer, CA125 has been widely used as an early screening test for ovarian cancer [3] It is elevated in more than 80% of patients with advanced stage ovarian cancer but only elevated in 50~60% of patients with stage I ovarian cancer, which is somewhat less sensitive in the early stage [4]. Cancer cells produce more exosomes than normal cells, and it is reported that cancerderived exosomes can promote invasion and proliferation by intercellular communication in tumor microenvironment [10,11] Many biomolecules such as mRNAs, proteins, miRNAs have been identified in exosomes; researchers have had a great deal of interest in exosomes mainly because exosomes may play a role in cell to cell signaling through the transport of miRNAs, growth factors, and other small molecules [12]. The aim of the study was to identify serum exosomal miRNAs as a biomarker for early and differential diagnosis of EOC and we compared its expression both in tissues and exosome in serum of patients with EOC and benign ovarian neoplasm, and tried to find out the expression of the target gene of the miRNA in tissues of EOC and benign ovarian neoplasm
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
